[go: up one dir, main page]

WO2009122034A3 - Nouveaux derives de carbazole inhibiteurs d'ηsp90, compositions les contenant et utilisation - Google Patents

Nouveaux derives de carbazole inhibiteurs d'ηsp90, compositions les contenant et utilisation Download PDF

Info

Publication number
WO2009122034A3
WO2009122034A3 PCT/FR2009/000267 FR2009000267W WO2009122034A3 WO 2009122034 A3 WO2009122034 A3 WO 2009122034A3 FR 2009000267 W FR2009000267 W FR 2009000267W WO 2009122034 A3 WO2009122034 A3 WO 2009122034A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
novel
dhsp90
inhibitory
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2009/000267
Other languages
English (en)
Other versions
WO2009122034A2 (fr
WO2009122034A8 (fr
Inventor
Marcel Alasia
Luc Bertin
Victor Cerval
Frank Halley
Patrick Mailliet
Maria Mendez Perez
Hervé MINOUX
Jean-Marie Ruxer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39930567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009122034(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CN2009801174385A priority Critical patent/CN102026992A/zh
Priority to CA2718488A priority patent/CA2718488A1/fr
Priority to MX2010010018A priority patent/MX2010010018A/es
Priority to EA201071078A priority patent/EA201071078A1/ru
Priority to BRPI0909731-7A priority patent/BRPI0909731A2/pt
Priority to AU2009232121A priority patent/AU2009232121A1/en
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to EP09728587A priority patent/EP2265598A2/fr
Priority to JP2010550234A priority patent/JP5674483B2/ja
Publication of WO2009122034A2 publication Critical patent/WO2009122034A2/fr
Publication of WO2009122034A3 publication Critical patent/WO2009122034A3/fr
Priority to TNP2010000351A priority patent/TN2010000351A1/fr
Publication of WO2009122034A8 publication Critical patent/WO2009122034A8/fr
Priority to IL208059A priority patent/IL208059A0/en
Priority to US12/881,414 priority patent/US8309721B2/en
Anticipated expiration legal-status Critical
Priority to MA33221A priority patent/MA32206B1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne les nouveaux produits de formule (I) : dans lesquels Het représente un hétérocycle éventuellement substitué par un ou plusieurs radicaux R1 ou R'1, R est choisi dans le groupe constitué par FORMULE(II) avec R1 et/ou R'1, choisis parmi H, halogène, CF3, nitro, cyano, alkyle, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, phénylalcoxy, alkylthio, carboxy libre ou estérifié par un radical alkyle, carboxamide, CO-NH(alkyl), CON(alkyl)2, NH-CO- alkyl, sulfonamide, NH-S02-alkyl, S(0)2-NHalkyl, S(O2)-N(alkyl)2; tous ces radicaux éventuellement substitués; W1, W2, W3 représentent indépendemment CH ou N, X représente O, S, NR2, C(O), S(O) ou S(0)2; Z représente H, HaI, -0-R2 ou -NH-R2 avec R2 représente H, alkyle, cycloalkyle ou hétérocycloalkyle éventuellement substitués; ces produits étant sous toutes les formes isomères et les sels, à titre de médicaments.
PCT/FR2009/000267 2008-03-14 2009-03-13 Nouveaux derives de carbazole inhibiteurs d'ηsp90, compositions les contenant et utilisation Ceased WO2009122034A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2010550234A JP5674483B2 (ja) 2008-03-14 2009-03-13 新規なｈｓｐ９０阻害性カルバゾール誘導体、同誘導体を含む組成物およびその使用
EP09728587A EP2265598A2 (fr) 2008-03-14 2009-03-13 Nouveaux derives de carbazole inhibiteurs d' hsp90, compositions les contenant et utilisation
CA2718488A CA2718488A1 (fr) 2008-03-14 2009-03-13 Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
MX2010010018A MX2010010018A (es) 2008-03-14 2009-03-13 Nuevos derivados de carbazol inhibidores de hsp90, composiciones que los contienen y su uso.
EA201071078A EA201071078A1 (ru) 2008-03-14 2009-03-13 Новые производные карбазола, являющиеся ингибиторами hsp90, содержащие их композиции и их применение
BRPI0909731-7A BRPI0909731A2 (pt) 2008-03-14 2009-03-13 derivados de carbazol inibidores de hsp90, composições que os contêm e a respectiva utilização
AU2009232121A AU2009232121A1 (en) 2008-03-14 2009-03-13 Novel HSP90 inhibitory carbazole derivatives, compositions containing same, and use thereof
CN2009801174385A CN102026992A (zh) 2008-03-14 2009-03-13 新的hsp90抑制性咔唑衍生物和含有该咔唑衍生物的组合物及其用途
TNP2010000351A TN2010000351A1 (en) 2009-03-13 2010-07-27 Novel hsp90 inhibitory carbazole derivatives compositions containing same and use thereof
IL208059A IL208059A0 (en) 2008-03-14 2010-09-07 Novel hsp90 inhibitory carbazole derivatives, compositions containing same and use thereof
US12/881,414 US8309721B2 (en) 2008-03-14 2010-09-14 HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof
MA33221A MA32206B1 (fr) 2008-03-14 2010-10-06 Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0801394A FR2928645A1 (fr) 2008-03-14 2008-03-14 Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
FR08/01394 2008-03-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/881,414 Continuation US8309721B2 (en) 2008-03-14 2010-09-14 HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof

Publications (3)

Publication Number Publication Date
WO2009122034A2 WO2009122034A2 (fr) 2009-10-08
WO2009122034A3 true WO2009122034A3 (fr) 2009-12-03
WO2009122034A8 WO2009122034A8 (fr) 2010-08-19

Family

ID=39930567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2009/000267 Ceased WO2009122034A2 (fr) 2008-03-14 2009-03-13 Nouveaux derives de carbazole inhibiteurs d'ηsp90, compositions les contenant et utilisation

Country Status (24)

Country Link
US (1) US8309721B2 (fr)
EP (1) EP2265598A2 (fr)
JP (1) JP5674483B2 (fr)
KR (1) KR20100130603A (fr)
CN (1) CN102026992A (fr)
AR (1) AR070836A1 (fr)
AU (1) AU2009232121A1 (fr)
BR (1) BRPI0909731A2 (fr)
CA (1) CA2718488A1 (fr)
CL (1) CL2009000619A1 (fr)
CO (1) CO6251295A2 (fr)
CR (1) CR11653A (fr)
DO (1) DOP2010000272A (fr)
EA (1) EA201071078A1 (fr)
EC (1) ECSP10010473A (fr)
FR (1) FR2928645A1 (fr)
IL (1) IL208059A0 (fr)
MA (1) MA32206B1 (fr)
MX (1) MX2010010018A (fr)
NI (1) NI201000150A (fr)
PE (1) PE20091673A1 (fr)
TW (1) TW200938541A (fr)
UY (1) UY31711A (fr)
WO (1) WO2009122034A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8912181B2 (en) 2011-01-07 2014-12-16 Taiho Pharmaceutical Co., Ltd. Bicyclic compound or salt thereof

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011035416A1 (fr) * 2009-09-25 2011-03-31 Aegera Therapeutics Inc. Composés modulateurs de la hsp90, compositions, procédés et utilisations correspondants
WO2012093707A1 (fr) 2011-01-07 2012-07-12 大鵬薬品工業株式会社 Nouveau dérivé de l'indole ou de l'indazole ou sel de celui-ci
JP5842630B2 (ja) * 2011-03-16 2016-01-13 株式会社リコー カルバゾール誘導体、及び半導体ナノ結晶
JP2014075556A (ja) * 2012-10-05 2014-04-24 Idemitsu Kosan Co Ltd 有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子
WO2014108168A1 (fr) * 2013-01-10 2014-07-17 Merck Patent Gmbh Pipéridinylcarbazole comme antipaludique
EP3059225A4 (fr) 2013-10-17 2017-09-06 Shionogi & Co., Ltd. Nouveau dérivé d'alkylène
CA2932609A1 (fr) 2013-12-05 2015-06-11 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
AU2015291788A1 (en) * 2014-07-16 2016-11-24 Novogen ltd Functionalised and substituted carbazoles as anti-cancer agents
PT3201177T (pt) * 2014-10-01 2019-02-12 Univ Leuven Kath Indóis mono- ou di-substituídos como inibidores de replicação viral do dengue
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AU2016255510A1 (en) * 2015-04-29 2017-11-23 Arena Pharmaceuticals, Inc. 1-heteroaryl-indoline-4-carboxamides as modulators of GPR52 useful for the treatment or prevention of disorders related thereto
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) * 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
DE102016122122B4 (de) * 2015-11-18 2021-02-11 Cynora Gmbh Organische Moleküle, insbesondere zur Verwendung in organischen optoelektronischen Vorrichtungen
US9966542B2 (en) * 2016-06-02 2018-05-08 E I Du Pont De Nemours And Company Electroactive materials
DE102017008073A1 (de) * 2017-08-28 2019-02-28 Henkel Ag & Co. Kgaa Neue anionische Tenside und Wasch- und Reinigungsmittel, welche diese enthalten
CN111217741B (zh) * 2019-03-01 2022-03-15 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 氟取代单咔唑类衍生物、其制备方法及应用
CN118834213A (zh) * 2022-04-28 2024-10-25 北京丹擎医药科技有限公司 三环杂环衍生物及其组合物和应用
CN120603829A (zh) * 2023-03-31 2025-09-05 上海翊维康医药有限责任公司 杂芳环化合物及其制备方法和用途
CN117229196A (zh) * 2023-08-23 2023-12-15 贵州省茶叶研究所 一类水杨醛咔唑化合物及其应用
CN117159570B (zh) * 2023-11-01 2024-01-23 云南中医药大学 6-酰氧基甘露糖叠氮乙苷衍生物与氟康唑联合在制备抗耐药白念珠菌药物中的应用
CN117486782A (zh) * 2023-12-29 2024-02-02 中国医学科学院药用植物研究所 一种n-取代咔唑衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036597A1 (fr) * 2000-11-03 2002-05-10 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Derives tricycliques de l'indole a activite anti-angiogenique
WO2006055760A1 (fr) * 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Composes triazole modulant l'activite de hsp90

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035620A2 (fr) * 2005-09-16 2007-03-29 Serenex, Inc. Derives de carbazole
US8405508B2 (en) 2006-08-09 2013-03-26 Emd Millipore Corporation Use of gamma hardened RFID tags in pharmaceutical devices

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036597A1 (fr) * 2000-11-03 2002-05-10 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Derives tricycliques de l'indole a activite anti-angiogenique
WO2006055760A1 (fr) * 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Composes triazole modulant l'activite de hsp90

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8912181B2 (en) 2011-01-07 2014-12-16 Taiho Pharmaceutical Co., Ltd. Bicyclic compound or salt thereof

Also Published As

Publication number Publication date
MX2010010018A (es) 2010-12-15
MA32206B1 (fr) 2011-04-01
DOP2010000272A (es) 2010-10-15
UY31711A (es) 2009-11-10
TW200938541A (en) 2009-09-16
KR20100130603A (ko) 2010-12-13
PE20091673A1 (es) 2009-11-14
EP2265598A2 (fr) 2010-12-29
EA201071078A1 (ru) 2011-04-29
AR070836A1 (es) 2010-05-05
CO6251295A2 (es) 2011-02-21
US8309721B2 (en) 2012-11-13
CN102026992A (zh) 2011-04-20
NI201000150A (es) 2011-03-29
US20110166169A1 (en) 2011-07-07
AU2009232121A1 (en) 2009-10-08
JP5674483B2 (ja) 2015-02-25
WO2009122034A2 (fr) 2009-10-08
WO2009122034A8 (fr) 2010-08-19
BRPI0909731A2 (pt) 2019-03-06
CA2718488A1 (fr) 2009-10-08
JP2011513473A (ja) 2011-04-28
ECSP10010473A (es) 2010-10-30
CL2009000619A1 (es) 2011-02-18
IL208059A0 (en) 2010-12-30
CR11653A (es) 2010-11-22
FR2928645A1 (fr) 2009-09-18

Similar Documents

Publication Publication Date Title
WO2009122034A3 (fr) Nouveaux derives de carbazole inhibiteurs d&#39;ηsp90, compositions les contenant et utilisation
EA200870192A1 (ru) Новые серосодержащие производные циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
NO20071125L (no) Substituerte indolyl-alkyl-aminoderivater som nye inhibitorer av histondeacetylase
MX2012012111A (es) Inhibidores de demetilasa-1 especifica de lisina y su uso.
EA201101334A1 (ru) Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их
NO20071117L (no) Substituerte propenyl-piperazinderivater som nye inhibitorer av histondeacetylase
MX2011009806A (es) Nuevos derivados de indazol inhibidores de hsp90, composiciones que los contienen y su uso.
DK1981871T3 (da) Heterocyclylalkylderivater som hidtil ukendte inhibitorer af histondeacetylase
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
EA201070039A1 (ru) Спироциклы в качестве ингибиторов 11-бета гидроксилстероиддегидрогеназы типа 1
WO2009006404A3 (fr) Composés hétérocycliques utiles en tant qu&#39;inhibiteurs de la kinase raf
WO2007083017A3 (fr) Nouveaux derives d&#39;uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
NO20085212L (no) Nye pyridinanaloger
DK1981874T3 (da) Aminophenylderivater som nye inhibitorer af histondeacetylase
WO2008051873A3 (fr) Inhibiteurs d&#39;époxyde hydrolase soluble
EA201000101A1 (ru) Производные пиримидина 934
NO20085214L (no) Nye pyridinanaloger
MX2020014087A (es) Moléculas inmunomoduladoras pequeñas novedosas.
EA201071269A1 (ru) 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина
WO2009080432A3 (fr) Composition destinée au traitement de la tuberculose
WO2012033548A3 (fr) Oxo-hétérocycles et sulfono-hétérocycles bis-azotés herbicides
EA200970364A1 (ru) Новые производные имидазолонов в качестве лекарственных средств, способ их получения, фармацевтические композиции и применение в качестве ингибиторов протеинкиназ, в частности, cdc7
NO20060963L (no) Nikotinamidderivater anvendelige som PDE4-inhibitorer
NO20091972L (no) Nye fluorenderivater, sammensetninger inneholdende dem og anvendelse derav som inhibitorer av protein chaperone HSP 90
WO2010056585A3 (fr) Composés hétéroaryl-diamide utiles en tant qu&#39;inhibiteurs de mmp-13

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980117438.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09728587

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: DZP2010000488

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 201011653

Country of ref document: CR

Ref document number: CR2010-011653

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 10108118

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 12010502011

Country of ref document: PH

REEP Request for entry into the european phase

Ref document number: 2009728587

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009728587

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3319/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/010018

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1001142

Country of ref document: KE

Ref document number: 20107020403

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010550234

Country of ref document: JP

Ref document number: 587954

Country of ref document: NZ

Ref document number: 2718488

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PI 2010004304

Country of ref document: MY

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009232121

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009232121

Country of ref document: AU

Date of ref document: 20090313

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201071078

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: A201012146

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0909731

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100914